Guselkumab Versus Risankizumab for Ulcerative Colitis: Real-World Comparison of Post-Induction Outcomes.

Tremfya (guselkumab) - J&J

Skyrizi (risankizumab-rzaa) - AbbVie, Boehringer Ingelheim

http://www.ncbi.nlm.nih.gov/pubmed/42777856

Alex D Carlin; Emma L McClure; Jessica R Allegretti; Karen M Kwaning; Mia E Silvestri; Rahul S Dalal

Sep 24, 2026